Current therapeutic options in metastatic castration-resistant prostate cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference106 articles.
1. 1999–2013 Incidence and Mortality Web-based Report. [Internet]. Atlanta: U.S. Department of Health and Human Services,2016
2. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer;Cornford;Eur Urol,2017
3. Prevalence of prostate cancer clinical states and mortality in the United States: estimates using a dynamic progression model;Scher;PLoS One,2015
4. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer;O'Donnell;Br J Cancer,2004
5. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy;Ryan;J Clin Oncol,2010
Cited by 63 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Natural sapogenins as potential inhibitors of aquaporins for targeted cancer therapy: computational insights into binding and inhibition mechanism;Journal of Biomolecular Structure and Dynamics;2024-01-04
2. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2023-11-07
3. Effect of food and polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers;British Journal of Clinical Pharmacology;2023-09-18
4. Molecular Targeted Radionuclide Therapy for Prostate Cancer;Molecular Imaging and Therapy;2023-09-17
5. [177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial;Journal of Nuclear Medicine;2023-09-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3